Drugs / Luteinizing Hormone
Luteinizing Hormone
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01037699 | Jan 2005 → Mar 2008 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06803199 | Dec 2024 → Dec 2026 expected | — | Kaohsiung Veterans General Hospital. | Recruiting | No outcome recorded |
| — | NCT06560086 | Feb → Dec 2024 | cryptorchidism | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Luteinizing Hormone | “The combined use of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) has improved IVF pregnancy rates in infertile women aged 35-40” NCT06803199 ↗ |
| Known as | LH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06803199 ↗ |
| Known as | Recombinant Luteotrophin alfa | “rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)” NCT01037699 ↗ |
| Known as | rLH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01037699 ↗ |
| Action | Activate | “Conversely, 14 days of luteinizing hormone stimulation lead to elevated levels of Trem2 and insulin-like 3 in the testes compared to the untreated control group.” NCT06560086 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Luteotrophin alfa” NCT01037699 ↗ |